Observational studyJournal of thrombosis and thrombolysis2017
Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes.
Observational study in Journal of thrombosis and thrombolysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (START): design and rationale of the START pilot randomized controlled trial.Research and practice in thrombosis and haemostasis · 2025Article
- Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review.Acta haematologica · 2025Review
- Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.Annals of hematology · 2024Article
- Challenging clinical scenarios for therapeutic anticoagulation: A practical approach.Thrombosis research · 2022Review
- EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.HemaSphere · 2022Article
- Management of cancer-associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement.Research and practice in thrombosis and haemostasis · 2022Article
- Safety and outcomes of thrombolytic therapy in patients with pulmonary embolism and thrombocytopenia: A systematic review.Qatar medical journal · 2022Article
- Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study.Blood advances · 2021Observational
- Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy.Journal of thrombosis and thrombolysis · 2021Article
- Review
- Challenges and Advances in Managing Thrombocytopenic Cancer Patients.Journal of clinical medicine · 2021Review
- Cancer-associated thromboembolism: antithrombotic management of hospitalized patients.Journal of thrombosis and thrombolysis · 2020Observational
- Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.Hematology. American Society of Hematology. Education Program · 2019Article
- Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.Blood advances · 2019Review
- Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.Research and practice in thrombosis and haemostasis · 2018Article
- Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus.TH open : companion journal to thrombosis and haemostasis · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is a common complication of hematologic malignancies. Prolonged periods of thrombocytopenia are experienced universally by patients undergoing treatment for these diseases, yet data to guide management of anticoagulation in this setting are lacking. To obtain data on the management and outcomes of VTE in patients with thrombocytopenia related to the treatment of hematologic malignancies. This was an observational cohort study of patients experiencing VTE during periods of treatment-related thrombocytopenia over a 5-year period at the Fred Hutchinson Cancer Research Center. Medical records were reviewed for diagnostic, treatment and outcomes data, including bleeding events (categorized by WHO criteria) and progression or recurrence of VTE. Eighty-two patients meeting inclusion criteria were identified. Forty-eight percent were male and the median age was 55. Sixty-seven patients received anticoagulation, 88% of these were managed with transfusion support for a platelet goal of 50 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.